Cargando…

Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease

Increasing evidence supports a role for abnormal immune activation and inflammatory responses in Huntington disease (HD). In this study, we evaluated the therapeutic potential of laquinimod (1 and 10 mg/kg), a novel immunomodulatory agent shown to be protective in a number of neuroinflammatory condi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garcia-Miralles, Marta, Hong, Xin, Tan, Liang Juin, Caron, Nicholas S., Huang, Yihui, To, Xuan Vinh, Lin, Rachel Yanping, Franciosi, Sonia, Papapetropoulos, Spyros, Hayardeny, Liat, Hayden, Michael R., Chuang, Kai-Hsiang, Pouladi, Mahmoud A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4985819/ https://www.ncbi.nlm.nih.gov/pubmed/27528441 http://dx.doi.org/10.1038/srep31652

Ejemplares similares

Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease
por: Teo, Roy Tang Yi, et al.
Publicado: (2016)

Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells
por: Dobson, Lucianne, et al.
Publicado: (2016)

Neonatal Iron Supplementation Induces Striatal Atrophy in Female YAC128 Huntington’s Disease Mice
por: Berggren, Kiersten L., et al.
Publicado: (2016)

Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease
por: Schmidt, Mandi E., et al.
Publicado: (2018)

DAPK1 Promotes Extrasynaptic GluN2B Phosphorylation and Striatal Spine Instability in the YAC128 Mouse Model of Huntington Disease
por: Schmidt, Mandi E., et al.
Publicado: (2020)

Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease
por: Van Raamsdonk, Jeremy M, et al.
Publicado: (2006)

Age-related mitochondrial alterations in brain and skeletal muscle of the YAC128 model of Huntington disease
por: Bečanović, Kristina, et al.
Publicado: (2021)

Author Correction: Age-related mitochondrial alterations in brain and skeletal muscle of the YAC128 model of Huntington disease
por: Bečanović, Kristina, et al.
Publicado: (2021)

Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse
por: Kusko, Rebecca, et al.
Publicado: (2018)

Differential Synaptic and Extrasynaptic Glutamate-Receptor Alterations in Striatal Medium-Sized Spiny Neurons of Aged YAC128 Huntington’s Disease Mice
por: Botelho, Eliã P., et al.
Publicado: (2014)

Antidepressant Effects of Probucol on Early-Symptomatic YAC128 Transgenic Mice for Huntington's Disease
por: de Paula Nascimento-Castro, Cristine, et al.
Publicado: (2018)

Temporal Characterization of Behavioral and Hippocampal Dysfunction in the YAC128 Mouse Model of Huntington’s Disease
por: de Paula Nascimento-Castro, Cristine, et al.
Publicado: (2022)

Correction: Differential Synaptic and Extrasynaptic Glutamate-Receptor Alterations in Striatal Medium-Sized Spiny Neurons of Aged YAC128 Huntington's Disease Mice
Publicado: (2017)

Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2017)

Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease
por: Carroll, Jeffrey B, et al.
Publicado: (2011)

Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease
por: Ellrichmann, Gisa, et al.
Publicado: (2011)

Transplantation of patient-derived adipose stem cells in YAC128 Huntington's disease transgenic mice
por: Im, Wooseok, et al.
Publicado: (2010)

Beyond Motor Deficits: Environmental Enrichment Mitigates Huntington’s Disease Effects in YAC128 Mice
por: Plácido, Evelini, et al.
Publicado: (2023)

Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signaling
por: Kramann, Nadine, et al.
Publicado: (2016)

Similar striatal gene expression profiles in the striatum of the YAC128 and HdhQ150 mouse models of Huntington’s disease are not reflected in mutant Huntingtin inclusion prevalence
por: Bayram-Weston, Zubeyde, et al.
Publicado: (2015)

Author Correction: Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2019)

Laquinimod reduces neuroaxonal injury through inhibiting microglial activation
por: Mishra, Manoj Kumar, et al.
Publicado: (2014)

Neural stem cells derived from the developing forebrain of YAC128 mice exhibit pathological features of Huntington’s disease
por: Li, Endan, et al.
Publicado: (2020)

A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington's disease
por: Kotowska-Zimmer, Anna, et al.
Publicado: (2022)

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study
por: Stasiolek, Mariusz, et al.
Publicado: (2015)

In vivo Dopamine Efflux is Decreased in Striatum of both Fragment (R6/2) and Full-Length (YAC128) Transgenic Mouse Models of Huntington's Disease
por: Callahan, Joshua W., et al.
Publicado: (2011)

In Vivo Roles of a Patient-Derived Induced Pluripotent Stem Cell Line (HD72-iPSC) in the YAC128 Model of Huntington’s Disease
por: Jeon, Iksoo, et al.
Publicado: (2014)

Solid Lipid Curcumin Particles Protect Medium Spiny Neuronal Morphology, and Reduce Learning and Memory Deficits in the YAC128 Mouse Model of Huntington’s Disease
por: Gharaibeh, Abeer, et al.
Publicado: (2020)

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
por: Brück, Wolfgang, et al.
Publicado: (2012)

Induced Pluripotent Stem Cell-Derived Neural Stem Cell Transplantations Reduced Behavioral Deficits and Ameliorated Neuropathological Changes in YAC128 Mouse Model of Huntington's Disease
por: Al-Gharaibeh, Abeer, et al.
Publicado: (2017)

A PET-CT study on neuroinflammation in Huntington’s disease patients participating in a randomized trial with laquinimod
por: Roussakis, Andreas-Antonios, et al.
Publicado: (2023)

Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis
por: Moore, Spencer, et al.
Publicado: (2013)

C57BL/6 Background Attenuates mHTT Toxicity in the Striatum of YAC128 Mice
por: Back, Michaela K., et al.
Publicado: (2021)

AAV-Dominant Negative Tumor Necrosis Factor (DN-TNF) Gene Transfer to the Striatum Does Not Rescue Medium Spiny Neurons in the YAC128 Mouse Model of Huntington's Disease
por: Alto, Laura Taylor, et al.
Publicado: (2014)

Huntingtin-Associated Protein 1A Regulates Store-Operated Calcium Entry in Medium Spiny Neurons From Transgenic YAC128 Mice, a Model of Huntington’s Disease
por: Czeredys, Magdalena, et al.
Publicado: (2018)

Human iPSC‐derived neural precursor cells differentiate into multiple cell types to delay disease progression following transplantation into YAC128 Huntington's disease mouse model
por: Park, Hyun Jung, et al.
Publicado: (2021)

Huntington’s Disease and Striatal Signaling
por: Roze, Emmanuel, et al.
Publicado: (2011)

Laquinimod Inhibits Inflammation-Induced Angiogenesis in the Cornea
por: Li, Zuohong, et al.
Publicado: (2020)

Laquinimod Supports Remyelination in Non-Supportive Environments
por: Nyamoya, Stella, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u77tah611h0jn6thonarps8945